Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeTopicsBioprocessingCell-Therapy Manufacturers Get Creative on Checking Particulates
Credit: koto_feja/ Getty Images
Manufacturers of cell-containing products are adopting new techniques to work around unclear regulatory guidance on particulates. That’s the experience of Diana Colleluori, PhD, principal chemistry, manufacturing and controls (CMC) consultant at Biologics Consulting.
According to Colleluori, cell-containing products can be harder to visually inspect for particulates, as they’re not clear and are often stored in opaque bags.
“Processing and testing cell-containing products already has challenges because they can’t be terminally sterilized,” she explains. “It’s also harder to make a visual assessment to meet regulatory requirements because they already contain cells and the final product is usually in a cell-freezing bag.”
The particulates are mostly (90%) plastic that enter the product from contact with the inside of single-use equipment used during manufacturing, she says, adding that other particulates can enter from product manipulation and, thus, it’s best to try to minimize this.
Companies that Colleluori has worked with have tackled this problem by running their process with the formulation buffer, but minus cells, she continues. This allows them to assess particulates in a clear solution, outside of a bag, which they can then extrapolate to running the same process with cells.
“By testing visible and sub-visible particles in those samples, you can prove your product contact materials are expected to meet the limits for your cell-containing products,” according to Colleluori.
The company can also run quality control tests on a small sample of the final product. Among the tests carried out are those based on the United States Pharmacopeia (USP) chapters 790 for visible particulates and injections,1790 for visual inspections of injections, and 788 for the sub-visible particles.
In addition, EU guidance on visual inspection of particles can also be relied upon. Which tests are run should depend on the method of administration, adds Colleluori.
“If you’re doing an intramuscular injection, it’s probably a little less rigorous than an intrathecal injection of products that have stricter regulations on the number of particles and sub-particles that can be present,” she says.
InsightsBiological drug productCell therapyIntramuscular administrationRegulatory policiesAlso of Interest
CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research CollaborationTop 10 Contract Development and Manufacturing Organizations 202610 CDMO Up & Comers 2026AI Accelerates Biomanufacturing from Discovery to TranslationNo One-Size-Fits-All Solution for Autologous Cell Therapy ManufacturingDesign for Commercial Scale from Day OneRelated Media
Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and SustainabilitySmart Vector Design for Improved Cell and Gene TherapiesFrom Functional Genomics to Cell Therapy: The Role of CRISPR-Based Gene EditingPrecision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene TherapiesASGCT 2024: A Video Update from BaltimoreGlobal Single-Use Network Support Assurance of SupplyTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
Copyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
